BERKELEY HEIGHTS, N.J., July 13, 2026
Tonix Pharmaceuticals announced a major managed Medicare payer agreement that will expand pharmacy coverage for TONMYA® (cyclobenzaprine HCl sublingual tablets) to approximately 9 million Medicare beneficiaries, representing about 16% of the U.S. Medicare population, beginning January 1, 2027. Combined with previously announced commercial payer agreements and Medicaid availability across most states, the company expects TONMYA to reach approximately 145 million covered lives, representing 46% of all covered lives in the United States. The expanded reimbursement footprint marks another significant milestone in the commercial rollout of the FDA-approved fibromyalgia treatment while supporting broader patient access nationwide.
Expanded Insurance Coverage Supports Commercial Growth Strategy
The new Medicare agreement builds upon two commercial coverage agreements that became effective during the second quarter of 2026 and complements Medicaid coverage representing approximately 73 million beneficiaries. Tonix stated that discussions with additional commercial insurers and Medicare payers remain ongoing as the company continues to strengthen market access for TONMYA. Company executives noted that increasing reimbursement coverage is expected to improve patient access while supporting prescription growth among healthcare providers seeking alternative treatment options for fibromyalgia.
Sales Force Expansion Reflects Positive Launch Momentum
Following recent reimbursement achievements and encouraging commercial launch metrics, Tonix is expanding its commercial organization to support increased physician engagement. The company plans to deploy 50 additional sales representatives by mid-third quarter 2026, increasing its field sales organization to approximately 150 representatives. According to the company, early launch indicators have shown positive trends across new prescribers, patient initiations, total prescriptions, and refill rates. Tonix also intends to increase marketing and medical affairs activities aimed at raising awareness of fibromyalgia and educating healthcare professionals about TONMYA as a first-in-class, non-opioid treatment designed for long-term daily bedtime administration.
Advertisement
TONMYA Addresses Longstanding Treatment Gap in Fibromyalgia
Approved by the U.S. Food and Drug Administration in August 2025, TONMYA became the first new prescription treatment for fibromyalgia in more than 15 years. The sublingual formulation delivers rapid transmucosal absorption of cyclobenzaprine while reducing formation of its long half-life metabolite by bypassing first-pass liver metabolism. Beyond its approved fibromyalgia indication, Tonix is also evaluating TNX-102 SL in Phase 2 clinical studies for major depressive disorder (MDD) and acute stress disorder (ASD). Supported by U.S. patent protection extending through 2034, the company continues advancing TONMYA as the cornerstone of its commercial central nervous system portfolio while pursuing additional pipeline programs across infectious diseases, immunology, and rare diseases.
Source: Tonix Pharmaceuticals, press release
